Targeted therapy for colon cancer uses non-steroidal anti-inflammatory drugs that target cyclooxygenases (COX-1 and COX-2), selective inhibitors of (COX-2) and selective inhibitors of ornithine decarboxylase (ODC), a rate-limiting enzyme in the polyamine biosynthesis pathway. This evidence concerns the gene ODC1 and malignant colon neoplasm.